RoslinCT, a leading global cell therapy Contract Development and Manufacturing Organization, today announced a strategic partnership with BlueRock Therapeutics, a leader in stem cell therapeutic ...

Biopharmaceutical developers should introduce risk-based, phase-appropriate characterization strategies for quality control ...

VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager ...

We spoke to developer of the HEK293 cell line, Frank Graham, about the challenges faced and serendipity required to pioneer a ...

STEMCELL Technologies and the Centre for Commercialization of Regenerative Medicine (CCRM) today announced a partnership to expand access to high-quality human induced pluripotent stem cell (iPSC) ...

Over the past decade, biologics development has moved from artisanal experimentation to a data-driven, platform-based discipline. Analytical depth has improved. Process integration has matured. Yet ...

ATUM, a leading US-based contract research organization, selected to support stable clonal cell line generation to advance VERAXA’s lead BiTAC-TCE program toward IND/CTA-enabling activities ...

Traditional approaches to biologics production—relying on one-size-fits-all expression vectors and empirical process optimization—have led to inefficiencies in expression, scalability, and ...

Cell line development is an essential step in the manufacture of biologics: drugs derived from living organisms, such as monoclonal antibodies, recombinant proteins and vaccines. In addition to this, ...

WHO-origin Master and Working Cell Banks provide vaccine developers with a ready-to-use Vero cell substrate for licensing, purchase, and integrated CDMO programs ...